Conversations on 
Twitter :
 |
|
|
|
@FierceBiotech: Industry Voices: Biosimilars and Trade Secrets. Feature | Follow @FierceBiotech
@JohnCFierce: ZS Pharma down in Fort Worth raised $46M in venture funds for clinical trial of kidney, liver disease drug. | Follow @JohnCFierce
@RyanMFierce: Radius has set its biotech IPO range $8.50-$10.50. Will it hit its price target and keep the streak alive? More | Follow @RyanMFierce
> After reporting upbeat Phase III results in PAH, Bayer has reported success in a late-stage study for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or those with persistent or recurrent pulmonary hypertension (PH) after surgery with the same experimental drug, riociguat. Release
> Eyeing the growing healthcare market in China, MicuRx Pharmaceuticals, a developer of antibiotics and Shanghai MengKe Pharmaceuticals have formed a joint venture to commercialize a candidate dubbed MRX-I in the Asian country. Item
> Bristol-Myers Squibb ($BMY) fell to a third-quarter loss in part because of its failed Hepatitis C program involving assets acquired in its $2.5 billion buyout of Inhibitex. Article
> Shire ($SHPG) has pledged $22 million over 5 years to support an alliance with a Italian biomedical charity, the Fondazion Telethon, to research new therapies for rare diseases. Release
> Pearl Therapeutics (a 2011 Fierce 15 company) has wrapped up a final Phase IIb study of its lead COPD therapy called PT003 and selected a dose for late-stage development of the experimental treatment. Release
> Cambridge, MA-based biotech Radius Health, which is developing an osteoporosis therapy, has set a price range of $8.50 to $10.50 for its initial public offering. Report
Pharma News
@FiercePharma: More pain for Big Pharma sales: Lilly's drop 11%, earnings fall short. Not as bad as BMS, though. More | Follow @FiercePharma
> Pharma wheels and deals in Europe as austerity wears on. Story
> GOP or Dem? Some pharma donors don't hedge their bets. Article
> BMS results crater on 96% drop in Plavix sales. News
@FierceMedDev: The FDA says it will focus more on quality in the device approval process. What that means may be an open question. More | Follow @FierceMedDev
@MarkHFierce: A medical device regulatory scandal erupts in Great Britain. Report | Follow @MarkHFierce
@DamianFierce: Thermo Fisher beats the Street again on soaring diagnostics sales. More | Follow @DamianFierce
> St. Jude's heart-plug future hinges on study data. Story
> EU notified bodies accused of improperly competing for device business. Article
> Bard nabs Neomend for $140M. News
> Zoll Medical launches Japan division. Report
Drug Delivery News
> Fuse Science rolls out roll-on delivery. News
> Biotecnol and PolyTherics team up to develop drug conjugates. Story
> Antibiotic Trojan horse for cholera may be possible. Item
> Oral flu vaccine melts in your mouth. More
Biomarkers News
> Genes might not be the key to antidepressant success after all. Story
> Blood test could predict breast cancer 20 years early. More
> Blood antibody pinpoints deadly preeclampsia. Article
> Researchers seek new pancreatic cancer biomarkers. Item
And Finally… A new Harvard study highlights to role of genetics in the placebo effect, which has befuddled drug developers for decades. Item